BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ISV-303: Phase I/II data

Top-line data from a double-blind, U.S. Phase I/II trial in 169 patients undergoing cataract surgery showed that a significantly greater proportion of patients receiving once-daily topical ISV-303 for 2 weeks following surgery achieved an absence of cells in the anterior chamber of the eye at day 15 post-treatment, the primary endpoint, vs. vehicle controls (53.5% vs. 19%, p=0.0016). Additionally, a...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >